None
Quote | Redhill Biopharma Ltd Ord (OTCMKTS:REDIF)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.67 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:29:59 pm |
News | Redhill Biopharma Ltd Ord (OTCMKTS:REDIF)
RedHill Biopharma Ltd. (RDHL) Q3 2021 Earnings Conference Call Nov 30, 2021 08:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and IR Manager Dror Ben-Asher - CEO Guy Goldberg - Chief Business Officer Gilead Raday - COO Rob Jackson - SVP, Sales and Marketing Micha...
The following slide deck was published by RedHill Biopharma Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: RedHill Biopharma Ltd. 2021 Q3 - Results - Earnings Call Presentation
Message Board Posts | Redhill Biopharma Ltd Ord (OTCMKTS:REDIF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd Ord Company Name:
REDIF Stock Symbol:
OTCMKTS Market:
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results Canada NewsWire RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation...
RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty b...
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Canada NewsWire - Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107...